Table 2. Significant genes for phenotype AD clinical diagnosis by meta VC-TWAS with filtered DPR weights.
Significant genes have FDR < 0.05 by meta-TWAS with ROS/MAP and Mayo Clinic cohorts. AD risk genes identified by previous GWAS are shaded in grey.
| Gene name | CHR | Start | End | P-value | FDR |
|---|---|---|---|---|---|
| ZNF234a | 19 | 44,645,710 | 44,664,462 | 1.11×10−16 | 1.40×10−12 |
| CLASRP a | 19 | 45,542,298 | 45,574,214 | 4.44×10−16 | 2.81×10−12 |
| TRAPPC6A a | 19 | 45,666,187 | 45,681,485 | 3.60×10−14 | 1.52×10−10 |
| TOMM40 a | 19 | 45,394,477 | 45,406,935 | 9.05×10−13 | 2.86×10−9 |
| MARK4 | 19 | 45,754,550 | 45,808,541 | 4.62×10−16 | 1.17×10−8 |
| PPP1R13L | 19 | 45,882,892 | 45,909,607 | 1.82×10−10 | 3.84×10−7 |
| CLPTM1 | 19 | 45,457,848 | 45,496,598 | 5.71×10−8 | 1.03×10−4 |
| EML2 | 19 | 46,112,660 | 46,148,726 | 1.88×10−7 | 2.97×10−4 |
| FBXO46 | 19 | 46,213,887 | 46,234,151 | 4.13×10−7 | 5.80×10−4 |
| CEACAM19 a | 19 | 45,174,724 | 45,187,631 | 3.93×10−6 | 4.68×10−3 |
| GIPR | 19 | 46,171,502 | 46,185,704 | 4.07×10−6 | 4.68×10−3 |
| RELB | 19 | 45,504,695 | 45,541,452 | 6.63×10−6 | 6.99×10−3 |
| ZNF225 | 19 | 44,617,548 | 44,637,255 | 2.59×10−5 | 2.51×10−2 |
a: Genes with significant p-values <0.0013 (Bonferroni correction with respect to 13 genes and 3 phenotypes) for at least one AD pathology phenotype